- Home
- RAND vs CYCC Comparison
RAND vs CYCC Comparison
Compare RAND & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- CYCC
- Stock Information
- Founded
- RAND 1969
- CYCC 1992
- Country
- RAND United States
- CYCC Malaysia
- Employees
- RAND N/A
- CYCC N/A
- Industry
- RAND Finance: Consumer Services
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- RAND Finance
- CYCC Health Care
- Exchange
- RAND Nasdaq
- CYCC Nasdaq
- Market Cap
- RAND 52.9M
- CYCC 47.6M
- IPO Year
- RAND N/A
- CYCC N/A
- Fundamental
- Price
- RAND $18.22
- CYCC $0.25
- Analyst Decision
- RAND
- CYCC Strong Buy
- Analyst Count
- RAND 0
- CYCC 1
- Target Price
- RAND N/A
- CYCC $11.00
- AVG Volume (30 Days)
- RAND 5.4K
- CYCC 7.3M
- Earning Date
- RAND 05-05-2025
- CYCC 05-20-2025
- Dividend Yield
- RAND 6.37%
- CYCC 59.13%
- EPS Growth
- RAND 39.63
- CYCC N/A
- EPS
- RAND 3.11
- CYCC N/A
- Revenue
- RAND $8,499,970.00
- CYCC $43,000.00
- Revenue This Year
- RAND N/A
- CYCC $137.21
- Revenue Next Year
- RAND N/A
- CYCC N/A
- P/E Ratio
- RAND $5.86
- CYCC N/A
- Revenue Growth
- RAND 12.52
- CYCC N/A
- 52 Week Low
- RAND $13.94
- CYCC $0.17
- 52 Week High
- RAND $31.89
- CYCC $3.08
- Technical
- Relative Strength Index (RSI)
- RAND 42.12
- CYCC 47.06
- Support Level
- RAND $18.00
- CYCC $0.28
- Resistance Level
- RAND $19.70
- CYCC $0.37
- Average True Range (ATR)
- RAND 0.79
- CYCC 0.07
- MACD
- RAND -0.02
- CYCC 0.01
- Stochastic Oscillator
- RAND 7.46
- CYCC 20.67
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.